Technical Analysis for ACAD - ACADIA Pharmaceuticals Inc.

Grade Last Price % Change Price Change
F 21.38 -4.08% -0.91
ACAD closed down 4.08 percent on Wednesday, December 6, 2023, on 86 percent of normal volume. It ran into resistance at its 50 day moving average.
5 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
50 DMA Resistance Bearish 0.00%
MACD Bearish Signal Line Cross Bearish 0.00%
Expansion Pivot Sell Setup Bearish Swing Setup 0.00%
BB Squeeze Ended Range Expansion 0.00%
Below Lower BB Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Fell Below 20 DMA Bearish -4.08%
Fell Below 50 DMA Bearish -4.08%
Bollinger Band Squeeze Range Contraction -4.08%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 1 ATR about 18 hours ago
Down 3% about 18 hours ago
60 Minute Opening Range Breakdown about 19 hours ago
Fell Below Lower Bollinger Band about 19 hours ago
Down 2 % about 22 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


ACADIA Pharmaceuticals Inc. Description

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. The company has a pipeline of product candidates led by pimavanserin, which is in Phase III development stage for the treatment of Parkinson's disease psychosis. It is also developing pimavanserin that has completed Phase II co-therapy trials for the treatment of schizophrenia; and is in Phase II clinical trials for the treatment of Alzheimer's disease psychosis. In addition, the company, through collaboration with Allergan, Inc., is developing alpha adrenergic agonists, which are in Phase II clinical trials for the treatment of chronic pain; and muscarinic agonist that is in Phase I clinical trials for the treatment of glaucoma. Further, it is developing two advanced preclinical programs directed at Parkinson's disease and other neurological disorders. The company was formerly known as Receptor Technologies, Inc. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Medication Alzheimer's Disease Chemical Compounds Parkinson's Disease Schizophrenia Chronic Pain Neurological Disorders Central Nervous System Disorders Nervous System Disorders Glaucoma Urological Disorders Treatment Of Parkinson's Disease Treatment Of Chronic Pain Treatment Of Glaucoma Treatment Of Schizophrenia Psychosis Treatment Of Alzheimer's Disease

Is ACAD a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 33.9069
52 Week Low 14.45
Average Volume 1,535,354
200-Day Moving Average 23.49
50-Day Moving Average 22.55
20-Day Moving Average 22.40
10-Day Moving Average 22.22
Average True Range 0.78
RSI (14) 39.76
ADX 9.88
+DI 18.31
-DI 28.30
Chandelier Exit (Long, 3 ATRs) 23.20
Chandelier Exit (Short, 3 ATRs) 23.55
Upper Bollinger Bands 23.27
Lower Bollinger Band 21.54
Percent B (%b) -0.09
BandWidth 7.69
MACD Line -0.22
MACD Signal Line -0.20
MACD Histogram -0.0295
Fundamentals Value
Market Cap 3.4 Billion
Num Shares 159 Million
EPS -1.97
Price-to-Earnings (P/E) Ratio -10.87
Price-to-Sales 19.85
Price-to-Book 12.93
PEG Ratio -0.42
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 23.43
Resistance 3 (R3) 23.59 23.08 23.09
Resistance 2 (R2) 23.08 22.56 22.99 22.97
Resistance 1 (R1) 22.23 22.23 21.97 22.06 22.86
Pivot Point 21.71 21.71 21.58 21.63 21.71
Support 1 (S1) 20.86 21.19 20.61 20.70 19.90
Support 2 (S2) 20.35 20.87 20.26 19.79
Support 3 (S3) 19.50 20.35 19.67
Support 4 (S4) 19.33